C84.37 Lymphoepithelioid lymphoma, spleen

Name of the Condition

• Lymphoepithelioid lymphoma, spleen (ICD-10 Code: C84.37)

Summary

Lymphoepithelioid lymphoma, spleen, is a rare subtype of mature T-cell lymphoma characterized by a distinctive histological pattern of epithelioid histiocytes and small lymphocytes. It typically presents as splenomegaly and may involve other extranodal sites. The condition is part of the broader category of peripheral T-cell lymphomas and is distinguished by its unique cellular composition, though its clinical behavior can vary.

Causes

The exact cause of lymphoepithelioid lymphoma is not fully understood. It is believed to involve genetic alterations in T-lymphocytes, leading to abnormal proliferation and tissue infiltration. Chronic antigen stimulation or immune dysregulation may contribute to its development, though specific triggers remain unclear. No consistent association with viral infections has been established.

Risk Factors

• Age: More common in adults, particularly those over 50.
• Immunosuppression: Conditions or treatments that weaken the immune system may increase risk.
• Genetic predisposition: Family history of lymphoma or related disorders.
• Ethnicity: Some studies suggest higher prevalence in certain populations, though data is limited.

Symptoms

• Painless enlargement of the spleen (splenomegaly).
• Fatigue or weakness.
• Unexplained weight loss.
• Fever or night sweats.
• Abdominal discomfort or fullness.

Diagnosis

Diagnosis typically involves a combination of imaging studies (e.g., CT or MRI) to assess splenic involvement, followed by a biopsy of the spleen or affected tissue. Histological examination reveals the characteristic mix of epithelioid histiocytes and small lymphocytes. Immunophenotyping and molecular testing may be used to confirm the T-cell origin and rule out other lymphomas. Staging evaluations assess disease extent.

Treatment Options

Treatment depends on disease stage and patient health. Options may include:

• Chemotherapy (e.g., anthracycline-based regimens).
• Immunotherapy (e.g., monoclonal antibodies).
• Splenectomy (surgical removal of the spleen) for localized disease.
• Radiation therapy for targeted areas.
• Clinical trials for novel therapies.

Prognosis and Follow-Up

Prognosis varies based on disease extent, response to treatment, and overall health. Regular follow-up with imaging and clinical assessments is essential to monitor for recurrence or progression. Long-term surveillance may be recommended, as late relapses can occur.

Complications

• Splenic rupture (rare but serious).
• Cytopenias (low blood cell counts) due to splenic dysfunction.
• Infection risk from impaired immune function.
• Transformation to a more aggressive lymphoma.

Lifestyle & Prevention

• Maintain a balanced diet and regular exercise to support overall health.
• Avoid exposure to infections when possible, especially if immunosuppressed.
• Follow-up with healthcare providers for routine check-ups.

When to Seek Professional Help

Seek medical attention if you experience persistent abdominal swelling, unexplained weight loss, fever, or fatigue. Prompt evaluation is important for early diagnosis and management.

Tips for Medical Coders

Document the anatomical site (spleen) clearly to support code assignment. Ensure biopsy results or imaging confirm splenic involvement. Code C84.37 is specific to the spleen; verify no other sites are documented to avoid miscoding.